Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Cash from Discontinued Operations (2016 - 2017)

Protalix BioTherapeutics (PLX) has 3 years of Cash from Discontinued Operations data on record, last reported at 2000.0 in Q3 2017.

  • For Q3 2017, Cash from Discontinued Operations rose 100.68% year-over-year to 2000.0; the TTM value through Sep 2017 reached 116000.0, down 97.19%, while the annual FY2016 figure was 11000.0, 100.74% down from the prior year.
  • Cash from Discontinued Operations reached 2000.0 in Q3 2017 per PLX's latest filing, up from 8000.0 in the prior quarter.
  • Across five years, Cash from Discontinued Operations topped out at 4138000.0 in Q4 2015 and bottomed at 1406000.0 in Q3 2015.
  • Average Cash from Discontinued Operations over 3 years is 159100.0, with a median of 131000.0 recorded in 2015.
  • Peak YoY movement for Cash from Discontinued Operations: surged 164.72% in 2016, then plummeted 101.25% in 2017.
  • A 3-year view of Cash from Discontinued Operations shows it stood at 4138000.0 in 2015, then plummeted by 107.15% to 296000.0 in 2016, then soared by 100.68% to 2000.0 in 2017.
  • Per Business Quant database, its latest 3 readings for Cash from Discontinued Operations were 2000.0 in Q3 2017, 8000.0 in Q2 2017, and 122000.0 in Q1 2017.